KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Nan Yu, Wenjie Xu, Xiaohui Guo, Mingtong Xu, Wei Zhang, Chaoli Yan, Shuguang Pang, Xiuhai Shu, Wei Zhang, Weixia Peng, Yawei Zhang, Gaixian Li, Xin Zhang, Dongmei Zhou

Diabetes Obes Metab 27(7) 3933-3942

PMID40302627
PMCIDPMC12146461
DOI10.1111/dom.16427
发表日期2025-04-30
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

AIM: Fotagliptin is a novel dipeptidyl peptidase-4 inhibitor for glycaemic control in patients with type 2 diabetes (T2D). This trial aimed to assess the efficacy and safety of fotagliptin add-on to metformin in patients with T2D. MATERIALS AND METHODS: In this phase 3 randomised, double-blind, placebo-controlled study, patients with T2D who had inadequate glycaemic control using metformin alone were randomly allocated to fotagliptin or placebo at a 2:1 ratio for 24-week double-blind treatment period, followed by an open-label treatment with fotagliptin for all patients, making up a total of 52 weeks. All eligible patients were treated with a stable dose of metformin (≥1500 mg per day). The primary endpoint was the change in HbA1c level from baseline to week 24. Safety was assessed in all patients who received at least one dose of the study drug. RESULTS: After 24 weeks, LS mean change of HbA1c from baseline was -0.81% with fotagliptin versus -0.28% with placebo. Estimated treatment difference for fotagliptin versus placebo of HbA1c was -0.53% (95% confidence interval [CI] -0.68% to -0.39%; p < 0.001). Significantly more patients on fotagliptin than on placebo achieved HbA1c < 7.0% after 24 weeks (38.7% vs. 16.9%; p < 0.001). The incidence of adverse events was similar between the two groups. No severe hypoglycaemia events were reported in patients treated with fotagliptin and metformin combined therapy. CONCLUSIONS: In patients with T2D who experienced inadequate glycaemic control with metformin, fotagliptin achieved a superior and clinically meaningful improvement in glycaemic control compared with placebo.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Patient disposition. Double‐blind treatment period FAS: Subjects who have used at least one double‐blind period trial medication after randomisation according to the intention‐to‐treat principle and for whom post‐dose efficacy data are available; Double‐blind treatment period SS: Subjects who have used at least one double‐blind period trial medication with safety evaluation. Extension treatment period FAS: Subjects who have used at least one extension period trial medication after randomisation according to the intention‐to‐treat principle and for whom post‐dose efficacy data are available; Extension treatment period SS: Subjects who have used at least one extension period trial medication with safety evaluation.
非 KM Figure
FIGURE 2FIGURE 2 Comparison of primary endpoints for fotagliptin versus placebo using full‐analysis set. (A) HbA1c values. (B) HbA1c change in the double‐blind period for patients in the full analysis set. Data are mean and error bars are standard errors (SEs). By analysis of covariance (ANCOVA) model, the change of relative baseline HbA1c in 24 weeks as the dependent variable, in the treatment group, for fixed effects, baseline HbA1c as a covariate. HbA1c values after rescue therapy were considered missing, and the missing week 24 HbA1c was filled by the LOCF method.
非 KM Figure
FIGURE 3FIGURE 3 Comparison of secondary endpoints for fotagliptin versus placebo using full‐analysis set. (A) Proportion of participants achieving HbA1c target of ≤6.5% and (B) proportion of participants achieving HbA1c target of < 7.0% in double‐blind period. (C) Fasting blood glucose (FBG) change in the double‐blind period. (D) Body weight change in the double‐blind period. Data are mean and error bars are standard errors (SEs).
非 KM Figure